Skip to main content
Thor Medical ASA logo

Thor Medical ASA — Investor Relations & Filings

Ticker · NANOV ISIN · NO0010597883 LEI · 5967007LIEEXZXG6DK30 OL Manufacturing
Open in API
Filings indexed 106 across all filing types
Latest filing 2025-08-04 Regulatory Filings
Country NO Norway
Listing OL NANOV

About Thor Medical ASA

https://www.thormedical.com/

Thor Medical ASA is a producer and supplier of alpha-particle emitters for cancer therapy. The company specializes in manufacturing isotopes, such as Thorium-228, by separating decay products from naturally occurring Thorium-232. This is achieved through a proprietary production technology that offers high efficiency, cost-competitiveness, and superior environmental friendliness. The company provides these critical alpha-emitters to partners developing next-generation targeted alpha therapies for precision oncology.

Recent filings

Filing Released Lang Actions
Thor Medical and AdvanCell expand strategic supply agreement for Thorium-228 - Attachment: Download announcement as PDF.pdf
Regulatory Filings Classification · 95% confidence The document is a press release from Thor Medical ASA announcing the expansion of a strategic supply agreement with AdvanCell. It details the increase in supply volume and purchasing commitment, which constitutes a significant corporate development. While it mentions 'Inside information' and regulatory disclosure requirements, it does not fit into specific categories like M&A (it is a supply agreement, not a merger or takeover), Earnings Release, or others. As it is a general regulatory announcement regarding a business partnership, it falls under the RNS (Regulatory Filings) category.
2025-08-04 English
Thor Medical and AdvanCell expand strategic supply agreement for Thorium-228
Regulatory Filings Classification · 95% confidence The document is a press release from Thor Medical ASA announcing the expansion of a strategic supply agreement with AdvanCell. It details the increase in supply volume and purchasing commitment, which constitutes a significant corporate development. While it mentions 'inside information' and regulatory disclosure requirements, it does not fit into specific categories like M&A (it is a supply agreement, not a merger or takeover), Earnings Release, or Financial Reports. As it is a general regulatory announcement regarding a business partnership, 'RNS' (Regulatory Filings) is the most appropriate fallback category.
2025-08-04 English
Thor Medical ASA - Share capital increase in relation to Subsequent Offering is registered - Attachment: Download announcement as PDF.pdf
Share Issue/Capital Change Classification · 100% confidence The document explicitly announces the registration of a share capital increase following a subsequent offering. It details the new share capital amount, the number of shares, and the nominal value per share. This aligns perfectly with the definition for 'Share Issue/Capital Change' (SHA), which covers announcements regarding new share issues and capital changes.
2025-08-01 English
Thor Medical ASA - Share capital increase in relation to Subsequent Offering is registered
Share Issue/Capital Change Classification · 100% confidence The document announces the registration of a share capital increase following a subsequent offering. It explicitly details the new share capital amount, the number of shares, and the nominal value per share. This falls directly under the category of announcements regarding new share issues or capital changes.
2025-08-01 English
Thor Medical ASA: Final results of the Subsequent Offering - Attachment: Download announcement as PDF.pdf
Share Issue/Capital Change Classification · 99% confidence The document is titled "Thor Medical ASA: Final results of the Subsequent Offering" and details the conclusion of a share offering, including the fact that it was oversubscribed, the board's resolution to issue shares, the gross proceeds raised (NOK 10 million), and the expected timeline for registration and delivery of shares. This content directly relates to fundraising, financing activities, and capital structure changes (issuance of new shares). This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it concerns a specific corporate finance action.
2025-07-04 Norwegian
Thor Medical ASA: Final results of the Subsequent Offering
Share Issue/Capital Change Classification · 99% confidence The document is titled "Thor Medical ASA: Final results of the Subsequent Offering" and details the outcome of a share offering, including the subscription period closing, board approval of allocation, gross proceeds raised (NOK 10 million), and expected registration dates. This clearly relates to a corporate action involving the issuance of new shares and capital structure changes. This aligns directly with the definition for Capital/Financing Update (CAP). It is not an Annual Report (10-K), an Earnings Release (ER), or a Dividend Notice (DIV). Since it contains the final results and details of the capital raise, it is the primary filing, not just an announcement of a report (RPA/RNS).
2025-07-04 Norwegian

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.